Septerna reports Q1 net loss $8.6M; cash $522M; positive Phase 1 data for SEP-631

Septerna, Inc.

2026-Q1 EPS reported -$0.19 revenue$26,523,000

Revenue from Novo Nordisk collaboration $26.5M; net loss improved to $8.6M from $21.5M YoY.
Cash $522.1M as of March 31, 2026; expected runway into 2029.
SEP-631 Phase 1 positive: well tolerated, supports once-daily dosing; Phase 2b in CSU planned H2 2026.
SEP-479 Phase 1 trial for hypoparathyroidism initiated; data expected late 2026/early 2027.
CMO Jae Kim departing; successor search initiated; will serve advisory role during transition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.